AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01974726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tubomanometry
Description: The test system is commercially available and can test ears with and without an intact tympanic membrane. Pressure sensors are inserted bilaterally into the ear canals and sealed. A controlled air-flow is introduced into the nose and nasopharynx and the subject swallows. ET openings are detected as a change in ME pressure measured directly as a pressure pulse in the ear canal for ears with a non-intact tympanic membrane or indirectly as a change in ear canal pressure caused by tympanic membrane displacement in ears with intact tympanic membranes. The outcome is the detection of a pressure change in the ear canal during swallowing which is indicative of a muscle-assisted tubal opening.
Study NCT01974726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Videoendoscopic assessment of ETF
Description: The subject's nose is topically anesthetized and decongested with 4% lidocaine and 0.05% oxymetazoline. If ventilation tubes are present, probes are sealed in the ear canal(s)and a pressure of 200 daPa is applied to the ME(s) to assess ET opening. If tympanic membranes are intact, microphones for sonotubometry are placed in the ear canals. Then, an endoscope attached to a video camera is introduced into the ipsilateral nasal cavity and focused on the ET orifice. For sonotubometry, the sound source probe is placed in the contralateral nostril. The subject is asked to swallow, vocalize and perform a series of mandibular movements. Signals from the video camera and pressure transducer or sonotubometry microphones are continuously recorded. The data are studied to document dilation of the nasopharyngeal ET orifice during swallowing and to rule in or out an anatomical or functional nasopharyngeal abnormality as the cause of a diagnosed ET dysfunction.
Study NCT01974726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pressure chamber ET test
Description: Performed in pressure chamber. Pressure increased to create middle-ear underpressure, then subject is asked to swallow several times. Middle-ear pressures are then measured by tympanometry. This is repeated with decreased chamber pressure, creating a middle-ear overpressure.
Study NCT01136668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block
Description: A high frequency (5-10 mHz) ultrasound probe (Sonosite Micromaxx, Licence No 12407) will be placed on the flank at the midpoint between the iliac crest and lower costal margin. The three muscle layers of external oblique, internal oblique, and transversus abdominis will be visualized. A 22G short-bevel block needle will be advanced in an anterior-to-posterior direction, in-plane with the probe, until the tip is visualized in the transversus abdominis plane. After negative aspiration, 0.4 ml/kg of bupivacaine 0.25% with 1:200,000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
Study NCT01136668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Circumferential subcutaneous infiltration of the ostomy wound with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg by the surgeon after skin closure.
Study NCT01467648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: (i) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml)will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem.
Study NCT01467648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: (ii) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml) will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem.
Study NCT03968614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric dry needling and conventional PT
Description: Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
Study NCT03968614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PT
Description: Eccentric Exercise, Stretching and Manual Therapy
Study NCT02935699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Drug (JDP-205)
Description: Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Study NCT02579239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Concentrate for solution for infusion
Study NCT02935699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control (Diphenhydramine)
Description: Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Study NCT00111917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: anti-TNF
Study NCT00111917 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion
Study NCT02066753 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mild therapeutic hypothermia
Description: Mild therapeutic hypothermia with a target temperature between 32-34°C.
Study NCT02066753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia
Description: Mild therapeutic hypothermia with a target temperature between 32-34°C.
Study NCT00012012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine trihydrate
Description: Amifostine will be delivered before each radiation treatment. Amifostine (500 mg) will be given as two equally-divided subcutaneous injections.
Study NCT00012012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m\^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
Study NCT00012012 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intracavitary brachytherapy
Description: For low dose rate (LDR) brachytherapy, cesium will be given in one to two intracavitary applications, within two weeks of completion of external radiation. The interval between the two applications will be one to three weeks. It is recommended that the total course of treatment be completed in less than eight weeks. High dose rate (HDR) brachytherapy may start as early as week two of external radiation. The minimum cumulative external and intracavitary dose should be 85 Gy.
Study NCT00012012 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: Patients will receive 1.8 Gy daily for five weeks for a total dose of 45 Gy; involved lateral parametrium and/or pelvic nodes should be boosted for a total dose (including intracavitary treatment) of 60 Gy ± 5%.
Study NCT02657915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT02657915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033 100mg/Kg
Description: Administered as specified in the treatment arm.
Study NCT01797744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Description: Usual rehabilitation and four different vestibular rehabilitation exercises, adapted to the individual patient
Study NCT04676074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Upper limb( body) ergometer
Description: Electronic pedal for the upper limb using for training the upper body. Intensity, speed and resistance can be adjusted.
Study NCT02022852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.
Study NCT02022852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: XELOX 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.
Study NCT03446651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysine Chloride
Description: Patients will receive 7 days of therapy using 115 mmol/day of lysine chloride. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
Study NCT03446651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 7 days of therapy using placebo. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
Study NCT04263220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Industrial passive exoskeleton with a specific value of the torque of the spring for supporting the back
Description: Both exoskeleton types are passive exoskeletons for supporting the back. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions
Study NCT04263220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protocol will be performed without exoskeleton
Description: protocol will be performed without exoskeleton
Study NCT01006174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean Oil
Description: Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.
Study NCT01006174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.
Study NCT01006174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
Study NCT01478737 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vitrectomy
Description: Vitrectomy only
Study NCT01224028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral
Study NCT03477097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition, exercise and social network intervention
Study NCT00905723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol
Description: 1 mg daily for 6 months
Study NCT00905723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoflavone
Description: 150 mg isoflavone daily for 6 months
Study NCT02719600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Evaluation of observational motor learning using virtual reality
Study NCT02719600 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: Evaluation of observational motor learning using virtual reality
Study NCT00905723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill daily for six months
Study NCT02925663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFI-E
Description: This is 10 web-based modules addressing foundational EF skills. Each online module will be accompanied by a videoconference with a therapist to review the skills and problem solve around adolescent-identified goals.
Study NCT03016026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS
Description: Undergo an ERAS program
Study NCT01170117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Dosing of olanzapine will begin at 2.5 mg and will be titrated to a maximum dose of 10 mg. The target dose of 10 mg of olanzapine was selected because published data from studies that used this dose indicated that it was helpful to patients.
Study NCT01170117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Group will receive placebo pill
Study NCT03720821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training + fMRI
Description: Consented subjects will be asked to participate in the study for up to five months. Patients will be consented at the Washington University Department of Anesthesiology and will be asked to complete baseline resilience, pain, and anxiety and depression questionnaires, along with cognitive tests by pencil and paper that will be administered by a member of the research team. The participants will also be required to complete a computer-based Trails-making test, Color Match test, and NCPT (Neurocognitive Performance Test) battery at baseline, and undergo a functional magnetic resonance imaging (fMRI) session.~All subjects will be asked to complete the three paper-pencil and computer-based measurements along with repeat pain questionnaire again 1-3 days after completion of training, undergo a second fMRI scan at that time, and complete the questionnaires again 3 months after the completion of training.
Study NCT02858154 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HFNC
Description: All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA
Study NCT02858154 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low flow oxygen by nasal cannula
Description: All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to manage sleep apnea
Study NCT04627493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise
Description: Participants will participate in an online exercise program on Zoom delivered by Registered Kinesiologists and Physiotherapists three times a week.
Study NCT04133298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunneling with laser de-epithelized gingival graft
Description: After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
Study NCT04133298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunnelingwith subepithelial connective tissue graf
Description: After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid
Study NCT03712345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1 low dose
Description: Single IV infusions of IFX-1
Study NCT03712345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1 high dose
Description: Single IV infusions of IFX-1
Study NCT03712345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02979301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 5 mg or 10 mg tamoxifen per day for 30 days.
Study NCT02107339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone 0.2 mg/kg administered at induction of anesthesia
Study NCT02107339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone 2 mg administered at the conclusion of anesthesia
Study NCT02200523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SARA electrode
Study NCT02200523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gold cup
Study NCT02464293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Description: An 8 week course of mindfulness-based cognitive therapy
Study NCT01180088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIGHT HEPATECTOMY WITH CLASSIC APPROACH
Description: The right portal branch and the right branch of the hepatic artery were identified, dissected and divided. Extraparenchymal ligation of pedicles for Sg4 was performed in case of extended right hepatectomy. The falciform and the right triangular ligaments were sectioned and the right liver up to the retrohepatic vena cava was totally mobilized by section and sutures of the accessory right hepatic veins. The right hepatic vein was controlled in an extrahepatic plane and encircled with a tape. At the end of parenchymal transection right hepatic vein was sectioned with endovascular stapler. The right bile duct and middle hepatic vein (in case of extended right hepatectomy) were divided intraparenchymally
Study NCT02363192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention and pharmacist support
Description: Patients randomised to this group will undergo an asthma assessment to assess asthma control, adherence and inhaler technique, by an Advanced Clinical Pharmacist specialising in Respiratory Medicine.
Study NCT03231722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: 6 mg/kg iv over 60 minutes, day 1
Study NCT01150292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: First period DHA
Description: 400 mg DHA supplementation by day for 2 weeks during the first study period
Study NCT01150292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Second period DHA
Description: 400 mg DHA supplementation by day for 2 weeks during the second study period
Study NCT01224028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01638507 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Resolute Integrity Stent
Description: Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
Study NCT02457026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
Study NCT02457026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
Study NCT06128473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Contact Lens
Description: Vision Correction
Study NCT02457026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.
Study NCT02457026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
Study NCT01424800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A disposable NIRS (near-infrared spectroscopy) sensor will be applied on the patient's forehead for continuous registration of the cerebral oxygen saturation.
Description: When the patient is on CPB, pressure and/or flow will be changed while continuously measuring ScO2. Temperature, CO2 , arterial oxygen content, hematocrit and anesthesia will be kept constant during the measurements. First, baseline MAP (mean arterial pressure), baseline ScO2 and baseline central venous oxygen saturation (SvO2) are determined. With the interventions, we will induce a change of 20% in MAP and/or flow. This is within the normal range during operations. Changes in blood pressure will be obtained by the use of vasoactive agents (sodiumnitroprusside for blood pressure decrease and phenylephrine for blood pressure increase). Flow is regulated by manual control of the pump flow. Values of the different variables will be obtained after a 5 min stabilisation period. Flow/pressure interventions will be randomized.
Study NCT04750421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transillumination Venolux®
Description: Transillumination Venolux® method was used on the other half of the face before injections to visualize veins.
Study NCT03231722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg iv over 60 minutes, day 1
Study NCT03231722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 150 mg/sqm iv over 60 minutes day 1